# Lycia Therapeutics files for IPO and seeks Nasdaq listing

_Published Monday, October 5, 2026 at 5:18 PM EDT · Capital · Latest · Tier 2 — Notable_

Lycia Therapeutics filed a registration statement on October 5 for a proposed initial public offering and applied to list its common stock on the Nasdaq Global Market under the symbol LYCA. The clinical-stage biotechnology company develops treatments designed to remove disease-causing proteins outside cells.

Lycia is conducting Phase 1 trials of LCA-0061 in participants with elevated immunoglobulin E, including food allergy patients, and LCA-0321 in patients with Graves' disease. The offering depends on Nasdaq listing approval, and Lycia cannot sell the securities until its registration statement becomes effective.

## Sources

- [SEC EDGAR](https://www.sec.gov/Archives/edgar/data/1806540/000162828026064973/lyciatherapeutics-drsa2.htm)

---
Canonical: https://techandbusiness.org/newswire/DijcZ4Llk6AIB4SSJOPnuG
Published: 2026-10-05T21:18:25.202Z
Story chronology: 2026-10-05T12:00:00.000Z
Retrieved: 2026-10-05T23:44:02.233Z
Publisher: Tech & Business (techandbusiness.org)